Among the many chemotherapeutic options for metastatic colorectal cancer, none has
shown clear superiority in efficacy. All pharmacologic agents in current use have been …

Colorectal cancer (CRC) is the third most common malignancy and cause of death from
cancer among adults worldwide. In recent years, the use of 5-fluorouracil-based regimens in …

During the last few years, research in symptom clusters and cooccurring linked toxicities has
markedly changed, progressively shifting from a simplistic descriptive picture to more …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the advantages and disadvantages of the various chemotherapeutic regimens used to treat …

Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36
million new cases and almost 700,000 deaths annually. Approximately 21% of patients with …

An increasing number of patients with metastatic colorectal cancer (mCRC) are able to
receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral …

Opinion statement Despite advances in screening procedures and the use of adjuvant
therapy, approximately 50% of patients with colorectal cancer eventually will develop …

Colorectal cancer represents a major health problem in the Western world. Many drugs have
been used for the treatment of this disease, but there is little information about how …

The treatment of colorectal cancer severely affects both patients suffering from colorectal
cancer and their families. To ensure that the patient is fully informed about the impact of …

Recommended combination regimens, which may include+ biologic agents as well as
standard chemotherapy, have a variety of toxicities. Toxicity management is key to ensuring …